Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking With The NHS and other Healthcare OrganisationsCollaborative WorkingCollaborative Working Project between The Société Internationale d’Oncologie Gériatrique and Pfizer Limited Collaborative Working Project between The Société Internationale d’Oncologie Gériatrique and Pfizer LimitedFrailty Service Toolkit - Supporting the identification and care of people living with cancer and frailty
Background
Cancer predominantly affects older individuals, with a significant portion of diagnoses and deaths occurring in patients aged 75 and older. These patients often present with additional health needs, including frailty, which complicates treatment and impacts quality of life. Frailty assessment is crucial for determining treatment eligibility, yet its application in older cancer patients is inconsistent. The International Society of Geriatric Oncology (SIOG) aims to address these challenges by developing a standardised frailty assessment toolkit.
Project
This collaborative project between SIOG and Pfizer aims to create a comprehensive service toolkit to standardise frailty assessment in older cancer patients. The toolkit will be developed through expert consensus, designed as an interactive digital material, and disseminated by both Pfizer and SIOG. The project will run from 4th August 2025 to 4th May 2026 and will include phases for planning, delivery, and evaluation.
Benefits
Benefits to patients
  • Improved assessment and consistent care.
  • Early recognition and intervention for frailty.
  • Enhanced quality of life and communication between care settings.
  • Reduced treatment discontinuation due to cancer therapy-related toxicity.

Benefits to the NHS
  • Specialist guidance and clinician education.
  • Innovative practices to improve care and reduce inequalities.
  • Promoting multidisciplinary team (MDT) working and enhancing personalised care.

Benefits to Pfizer
  • Demonstration of innovative practices.
  • Supporting NHS innovation and patient outcomes.
  • Insights into frailty assessment pathways.
  • Aligning to Pfizer values with equity of care.
Potential Outcomes
The project aims to improve awareness, education, and clinical pathways for frailty in cancer patients across the UK.
Proposed Term of the Collaborative Working Project
Planned start date: 4th August 2025.
Planned end date: 4th May 2026.
Resource Allocation
Pfizer UK Limited will contribute £54,076 funding and 108 hours of time to the project. The SIOG will contribute 648 hours of time to the project.
ResponsibilityHealthcare Organisation Grants

Pfizer is committed to being transparent about the relationships we have with other organisations. 

PartnershipsDonations and Grants

Find out about the donations and grants we make available to support healthcare, scientific research and education.

PP-UNP-GBR-12881 / August 2025
Science Products Responsibility Partnerships Careers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2025 Pfizer Limited. PP-UNP-GBR-13382  / September 2025. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427.  This website is intended for the general public in the UK.